Electromed vs Iridex
ELMD and IRIX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELMD and IRIX compare
Electromed is the larger company, worth 16 times as much as Iridex ($194M against $12.3M).
Electromed grew revenue faster over the last twelve months (15.3% versus −2.8% for Iridex).
Electromed keeps more of each dollar of sales as profit, with a net margin of 15.3% compared with −6.9% at Iridex.
Electromed scores higher on the StockData Score (21 against 8 for Iridex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELMD | IRIX |
|---|---|---|
| Size and price | ||
| Market cap | $194M | $12.3M |
| Share price | $23.13 | $0.700 |
| Change, 1 year | −8.5% | −28.6% |
| Change, 5 years | 100% | −89.3% |
| Beta (5Y) | 0.76 | 1.76 |
| Employees | 197 | 93 |
| StockData Score | ||
| Total score | 21 (better) | 8 |
| Valuation score | 5 (better) | 0 |
| Growth score | 5 (better) | 1 |
| Performance score | 5 (better) | 2 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.8× | – |
| P/S | 2.6× | 0.2× (better) |
| P/B | 3.6× (better) | 4.7× |
| EV/EBITDA | 12.5× | – |
| P/FCF | 23.0× | – |
| PEG | 0.33 | – |
| FCF yield | 4.3% (better) | −14.6% |
| Fair value | $31.99 | – |
| Margin of safety | 27.7% | – |
| Growth | ||
| Revenue growth (TTM) | 15.3% (better) | −2.8% |
| Revenue growth, 5Y average | 15.6% (better) | 7.7% |
| Net income growth (TTM) | 49.9% | – |
| EPS growth (TTM) | 52.9% | – |
| EPS growth, 5Y average | 36.9% | – |
| Profitability | ||
| Gross margin | 78.5% (better) | 38.2% |
| Operating margin | 18.8% (better) | −5.1% |
| Net margin | 15.3% (better) | −6.9% |
| FCF margin | 11.4% (better) | −3.7% |
| Return on equity | 23.3% (better) | −92.4% |
| Return on invested capital | 35.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.69 (better) | 1.76 |
| Altman Z-score | 12.67 (better) | −2.50 |
| Piotroski F-score | 8 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 2.0% | – |
| Shareholder yield | 2.0% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 55.6% | 12.4% |
| Held by insiders | 11.4% | 76.1% |
| Insider net buying, 12 months | −$2.2M | $536K (better) |
| Short interest, % of float | 2.4% | 0.94% |
Go deeper
- ELMD stock overview
- ELMD income statement
- ELMD valuation and score
- IRIX stock overview
- IRIX income statement
- IRIX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.